ArticleJTCVS open2025
Decoding intertumoral heterogeneity in multifocal ground-glass nodule lung cancers: Clonal evolutionary insight for precision management.
Article in JTCVS open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The management of multifocal ground-glass nodule (GGN) lung cancers remains hindered by insufficient knowledge of intertumoral heterogeneity, which complicates accurate diagnosis and effective treatment strategies. This study aims to characterize intertumoral heterogeneity of multifocal GGN lung cancers and to inform an evidence-based framework for diagnostic and therapeutic decision-making. Methods: We performed multiregion whole-exome sequencing (WES) on 60 surgically resected lung GGNs and their matched normal tissues. Clonal evolution analysis (CEA), focusing on subclonal expansion, was compared with comprehensive histologic assessment (CHA) to evaluate clonal relationships among multifocal lung GGNs. Longitudinal follow-up was conducted to validate the findings' robustness. Results: A total of 43 tumor pairs were included in the analysis. CEA classified 41 pairs (95.3%) as independent primary tumors (IPTs) and 2 pairs (4.7%) as intrapulmonary metastases (IMs). CHA initially identified 37 pairs (86.0%) as IPTs and 6 pairs (14.0%) as IMs. However, CEA reclassified 4 of the 6 CHA-identified IM pairs (66.7%) as IPTs, demonstrating superior diagnostic accuracy. Over a median follow-up of 57.5 months, 1 patient with IMs experienced recurrence and progression, whereas no such events occurred in patients with IPTs. Conclusions: CEA reveals noteworthy intertumoral heterogeneity in multifocal GGN lung cancers, highlighting the added diagnostic value of genetic profiling. Although most cases represent independent primaries, a subset aligns with metastatic processes, underscoring the need for vigilant assessment. These findings support a precision framework that integrates molecular data to optimize surveillance and therapeutic strategies, contributing to addressing the intertumoral heterogeneity challenges outlined in current management paradigms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.